The aim of the study was to compare bronchodilatating effect of inhaled salmeterol, salbutamol and both drugs administered simultaneously. 14 subjects (7 females, 7 men), aged 30-65 years (mean 49 yrs), suffering from moderate to severe asthma were examined. The improvement of FEV1 greater than 15% within 15 minutes of inhaling 200 micrograms of salbutamol was demanded. The study was performed in randomized, double-blinded, placebo controlled design. Throughout the study, all patients kept a daily score of symptoms and treatment. Each day of the trial, FEV1 in 30, 60, 120, 180 and 240 minute was measured. The statistically significant increase of FEV1 was noted only in 30 minute after salbutamol and in 180 minute after inhaling of salmeterol in comparison to salbutamol alone. No significant advantage of adding salbutamol to the patients previously treated with salmeterol was observed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Particularities of deposition of two ICS-LABA fixed dose combination dry powder aerosol drugs in the airways of COPD patients.
Respir Med
January 2025
Pulmonology Center of the Reformed Church, Munkácsy M. U.70, 2045, Törökbálint, Hungary.
The aim of this study was to analyse the effect of breathing parameters, age, gender and disease status on the lung doses of the two ICS + LABA fixed combination dry powder drugs. Breathing parameters of 113 COPD patients were measured while inhaling through emptied NEXThaler® and Ellipta® inhalers and the corresponding lung doses were calculated. Lung dose of Foster® NEXThaler® was superior to the lung dose of Relvar® Ellipta® in around 85 % of the patients.
View Article and Find Full Text PDFG-Protein-Coupled Receptor Surface Creates a Favorable Pathway for Membrane Permeation of Drug Molecules.
J Phys Chem Lett
December 2024
Frankfurt Institute for Advanced Studies, Ruth-Moufang-Straße 1, 60438 Frankfurt am Main, Germany.
Article Synopsis
- G-protein-coupled receptors (GPCRs), especially the β2-adrenergic receptor (β2AR), are vital for drug targeting in treating pulmonary diseases.
- Our study used coarse-grained molecular dynamics simulations to analyze how salmeterol and salbutamol interact with membranes and the β2AR, revealing that drug molecules often use the receptor surface for better membrane permeability.
- Findings indicate that enhancing drug interactions with GPCR surfaces could improve therapeutic effectiveness, presenting new avenues for drug development.
New ways to repurpose salmeterol in an animal model of fibromyalgia.
Fundam Clin Pharmacol
February 2025
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt.
Article Synopsis
- Fibromyalgia (FM) is a chronic pain syndrome linked to mood issues, sleep problems, and cognitive decline, possibly due to central pain processing dysfunction and neurotransmitter imbalances.* -
- In a study involving rats, reserpine was used to induce FM-like symptoms, revealing issues like increased pain sensitivity, depressive behaviors, and biochemical disturbances, which were reversed with the administration of salmeterol, a β2 receptor agonist.* -
- The findings suggest that treatments targeting β2 receptors, like salmeterol, could be an effective approach for managing symptoms associated with fibromyalgia.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!